glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ The FDA has approved the

Spatial transcriptomics mapped these populations to (i) the luminal epithelium (SOX9 + LGR5 + )

GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are medications developed to treat both type 2 diabetes and obesity by correcting hormonal imbalance - stimulating insulin release and suppressing excess glucagon -to bring blood sugar back under control

Lin J, Li X, Lu K, Song K, Wang L, Dai W, et al

Daily, consistent use is key

experimental studies with other GLP-1 analogues (exendin-4 and liraglutide) have shown evidence of inhibition of oxidative stress, decreased apoptosis and prevalence of injured cells, decreased vascular proliferation, and increased c AMP levels in neurons and anti-inflammatory activity in microglial cells [67]